文献速递艾滋病与性传播感染

低HIV-1 DNA病毒学控制成人中TDF/FTC维持策略的48周随机试验

Tenofovir disoproxil fumarate and emtricitabine maintenance strategy in virologically controlled adults with low HIV-1 DNA: 48 week results from a randomized, open-label, non-inferiority trial.
PubMed 文献 · J Antimicrob Chemother · 2021-01-01

TRULIGHT试验为多中心开放标签随机非劣效性研究,在HIV-DNA<2.7 log10 copies/106 PBMCs且无既往病毒学失败的病毒学抑制成人中,比较简化至替诺福韦二吡呋酯/恩曲他曲他滨(TDF/FTC)与继续三联方案。48周时TDF/FTC组88.5%、对照组90.9%维持pVL<50 copies/mL,虽显示非劣效,但TDF/FTC组病毒学失败伴耐药突变风险较低,不建议多数PLHIV使用该简化策略。

要点

  • 低HIV-DNA且无既往病毒学失败者可考虑简化至TDF/FTC,但需权衡耐药风险。
  • 48周TDF/FTC组病毒学失败6例(2例出现M184V/K65R),对照组2例。
  • 所有病毒学失败者在调整治疗后均重新抑制。

核心结论

  • 在低HIV-DNA病毒学抑制成人中,简化至TDF/FTC在48周显示非劣效,但因低风险病毒学失败伴耐药,不建议多数PLHIV使用。

研究设计与样本

  • 多中心、开放标签、随机非劣效性试验TRULIGHT(NCT02302547),筛查326例,随机223例至TDF/FTC组(n=113)或对照组(n=110)。

主要发现

  • 48周ITT分析TDF/FTC组100/113(88.5%)、对照组100/110(90.9%)维持pVL<50 copies/mL,ITT差异2.4%(95%CI -5.9至10.7),PP差异3.4%(95%CI -4.2至11.0)。
  • TDF/FTC组病毒学失败6例(其中2例出现M184V和K65R突变),对照组2例,ITT差异3.5%(95%CI -1.9至9.4)。
  • 所有病毒学失败者调整治疗后均重新抑制。

关键数值与推荐

  • 非劣效性界值为12%。
  • 入组条件:HIV-DNA<2.7 log10 copies/106 PBMCs,无既往病毒学失败。

临床怎么用

  • 对于病毒学抑制且低HIV-DNA的PLHIV,简化至TDF/FTC可作为选择,但需密切监测病毒载量并警惕耐药。
  • 因存在病毒学失败伴耐药风险,该策略不应推广至多数PLHIV。

局限性

  • 开放标签设计可能引入偏倚。
  • 样本量有限,病毒学失败事件较少,耐药风险估计需更大样本验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Low HIV reservoirs may be associated with viral suppression under a lower number of antiretroviral drugs. We investigated tenofovir disoproxil fumarate/emtricitabine as a maintenance strategy in people living with HIV (PLHIV) with low HIV-DNA. METHODS: TRULIGHT (NCT02302547) was a multicentre, open-label, randomized trial comparing a simplification to tenofovir disoproxil fumarate/emtricitabine versus a triple regimen continuation (tenofovir disoproxil fumarate/emtricitabine with a third agent, control arm) in virologically suppressed adults with HIV-DNA <2.7 log10 copies/106 PBMCs and no prior virological failure (VF). The primary endpoint (non-inferiority margin 12%) was the percentage of participants with a plasma viral load (pVL) <50 copies/mL in ITT (Snapshot approach) and PP analyses at Week 48 (W48). RESULTS: Of the 326 participants screened, 223 (68%) were randomized to the tenofovir disoproxil fumarate/emtricitabine arm (n = 113) or control arm (n = 110). At W48, the tenofovir disoproxil fumarate/emtricitabine and control arms maintained a pVL < 50 copies/mL in 100/113 (88.5%) and 100/110 (90.9%) participants, respectively (ITT difference 2.4%, 95% CI -5.9 to 10.7; PP difference 3.4%, 95% CI -4.2 to 11.0). Six VFs occurred in the tenofovir disoproxil fumarate/emtricitabine arm (two with emerging mutations M184V and K65R) versus two in the control arm (ITT difference 3.5%, 95% CI -1.9 to 9.4). All VFs were resuppressed after treatment modification. CONCLUSIONS: Although non-inferiority was shown, simplification to tenofovir disoproxil fumarate/emtricitabine should not be used for most PLHIV because of a low risk of VF with resistance.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Prazuck T, Verdon R, Le Moal G, et al. Tenofovir disoproxil fumarate and emtricitabine maintenance strategy in virologically controlled adults with low HIV-1 DNA: 48 week results from a randomized, open-label, non-inferiority trial. J Antimicrob Chemother. 2021. PMID: 33724373. doi:10.1093/jac/dkab038

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。